Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 26 of 46

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

CANbridge, WuXi expand rare disease partnership

These new candidates target rare genetic chronic diseases. According to the agreement, CANbridge has an exclusive regional or global rights for these therapies. WuXi Biologics will receive upfront,

Lilly to acquire Loxo Oncology for $8bn

Loxo Oncology is engaged in the development and commercialization of highly selective drug candidates for patients with genomically defined cancers. The company is developing targeted drugs that are

Otsuka, Click to develop digital therapeutics for MDD

This collaboration will leverage Click’s demonstrated ability to discover and validate a software application and deploy it commercially, with Otsuka’s expertise in developing approved prescription therapies for patients